+++ 821.390 Pressemeldungen +++ 33.973 Newsrooms +++ 6.000 Medien +++

Integrated Drug Discovery Alliance with Genentech

(PresseBox) (Hamburg, Germany, ) Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) today announced that it has entered into a multiyear integrated drug discovery alliance with Genentech Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), to discover novel small molecule therapeutics.

Evotec will apply its integrated and innovative drug discovery platform in combination with its extensive disease biology expertise against targets nominated by Genentech. This will include assay development and high throughput screening, medicinal chemistry and structural biology. The aim of the collaboration is to deliver high quality leads and development candidates to support Genentech's research efforts.

Further commercial details were not released.

Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: "We are proud that Genentech, one of the premier biopharmaceutical companies worldwide, has selected Evotec's scientists and innovative drug discovery platform to support their research efforts. We look forward to working closely with Genentech's scientists and achieving success together."

About Genentech

Founded more than 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines for patients with serious or lifethreatening medical conditions. The company, a wholly owned member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit www.gene.com.

About Evotec AG

Evotec is a leader in the discovery and development of novel small molecule drugs with operational sites in Europe and Asia. The Company has built substantial drug discovery expertise and an industrialised platform that can drive new innovative small molecule compounds into the clinic. In addition, Evotec has built a deep internal knowledge base in the treatment of diseases related to neuroscience, pain, oncology and inflammation. Leveraging these skills and expertise the Company intends to develop bestinclass differentiated therapeutics and deliver superior sciencedriven discovery alliances with pharmaceutical and biotechnology companies. Evotec has longterm discovery alliances with partners including Boehringer Ingelheim, CHDI, Novartis, Ono Pharmaceutical and Roche. Evotec has product candidates in clinical development and a series of preclinical compounds and development partnerships, including for example a strategic alliance with Roche for the EVT 100 compound family, subtype selective NMDA receptor antagonists for use in treatmentresistant depression. For additional information please go to www.evotec.com.

Diese Pressemitteilungen könnten Sie auch interessieren

News abonnieren

Mit dem Aboservice der PresseBox, erhalten Sie tagesaktuell und zu einer gewünschten Zeit, relevante Presseinformationen aus Themengebieten, die für Sie interessant sind. Für die Zusendung der gewünschten Pressemeldungen, geben Sie bitte Ihre E-Mail-Adresse ein.

Es ist ein Fehler aufgetreten!

Vielen Dank! Sie erhalten in Kürze eine Bestätigungsemail.